Abstract Body

INNODIA - Translational approaches to disease modifying therapy of type 1 diabetes: An innovative approach towards understanding and arresting Type 1 diabetes

The overall objective of INNODIA is to advance in a decisive way how we predict, stage, evaluate and prevent the onset and progression of type 1 diabetes (T1D). We are achieving this by creating novel tools, such as biomarkers, disease models and clinical trial paradigms. These tools allow us to distinguish and understand at the cellular and molecular level distinctive paths of ontogeny and progression in this heterogeneous disease, thus impacting on the future management of T1D patients and at risk individuals. We have established an interdisciplinary network of clinical and basic scientists, who are leading experts in the field of T1D in Europe, with complementary expertise from the areas of immunology, b-cell biology, biomarker research and T1D therapy, joining forces in a coordinated fashion between academic and industry partners, two foundations, as well as with patients with T1D and their families.

INNODIA follows over 600 people with newly diagnosed T1D with intensive biomarker measures. Over 4000 first degree family members of people with T1D have been screened of whom close to 300 have been found to have autoantibodies against the b-cell. Over 250 of these autoantibody-positive individuals accepted to be followed up intensively for biomarker research.

Since November 2020 INNODIA has initiated 4 clinical trials in people with newly diagnosed T1D (ranging from 5y to 45y). All trials are based on the INNODIA Masterprotocol follow up scheme and are using intensive CGM monitoring as a tool for glucose follow up.

More information on INNODIA and our clinical trials can be found on www.innodia.eu .